United States Clinical Trial Supplies Market By Clinical Phase (Phase I, Phase II, Phase III, Others), By Product & Services (Manufacturing, Storage & Distribution, Supply Chain Management), By Therapeutic Use (Oncology, CNS Diseases, Cardiovascular Diseases, Infectious Disease, Metabolic Disorders, Others), By End User (Pharmaceutical, Biologics, Medical device, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

The United States Clinical Trial Supplies Market was valued at USD 446.06 Million in 2024 and is expected to reach USD 638.33 Million by 2030 with a CAGR of 6.13%. The United States Clinical Trial Supplies Market is experiencing significant growth, driven by several key factors. A notable trend is the increasing complexity of clinical trials, particularly with the rise of personalized medicine and biologics. These therapies often require specialized handling, storage, and distribution, leading to a surge in demand for advanced supply chain solutions, including temperature-sensitive logistics and just-in-time delivery models. The expansion of decentralized clinical trials (DCTs) further contributes to this complexity, necessitating innovative approaches to patient recruitment, monitoring, and data collection. Companies are investing in digital technologies such as Internet of Things (IoT) devices and artificial intelligence (AI) to enhance supply chain management and ensure the timely delivery of clinical trial materials.

Despite these advancements, the market faces several challenges. The increasing complexity of clinical trials demands more sophisticated logistics and supply chain management, which can strain existing infrastructure and resources. Additionally, the rising costs associated with advanced supply chain solutions and regulatory compliance can impact the profitability of clinical trials. Regulatory requirements for clinical trial supplies are becoming more stringent, requiring companies to invest in compliance and quality assurance processes. Furthermore, geopolitical tensions and macroeconomic factors, such as inflation and fluctuating raw material costs, can disrupt global supply chains and affect the timely delivery of clinical trial materials.

Looking ahead, the market presents numerous opportunities. The adoption of digital solutions, including AI and blockchain, is expected to streamline supply chain operations and improve transparency. Collaborations between pharmaceutical companies and contract research organizations (CROs) can lead to more efficient trial designs and execution. The expansion of clinical trial sites, particularly in emerging markets, offers new avenues for patient recruitment and data collection. Additionally, the growing focus on patient-centric approaches and the integration of remote monitoring technologies can enhance patient engagement and retention in clinical trials.

Key Market Drivers

Rising Number of Clinical Trials Across Therapeutic Areas

The increasing number of clinical trials across diverse therapeutic areas is a significant driver for the growth of the United States Clinical Trial Supplies Market. Pharmaceutical, biotechnology, and medical device companies are expanding their research and development pipelines, leading to a surge in clinical research activities. This expansion is fueled by rising investments in drug discovery and innovation, coupled with the growing prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and autoimmune conditions. As new molecules and biologics enter the clinical stage, the demand for efficient and reliable supply chains becomes more critical. Sponsors require specialized logistics and packaging services to support complex protocols, manage temperature-sensitive products, and ensure timely delivery of investigational medicinal products (IMPs) to global trial sites.​

Recent data underscores this trend. According to the World Health Organization's International Clinical Trials Registry Platform (ICTRP), there has been a steady rise in the number of newly recruiting trials registered across most WHO regions, peaking in 2021. Although a decrease was observed in 2022 and 2023 in almost all regions, the South-East Asia region continued to grow, driven largely by trials in India. This sustained growth in clinical trial activity necessitates robust clinical trial supply chains to manage the increasing complexity and volume of trials. The rise of decentralized trials and direct-to-patient models has further increased the need for innovative supply strategies and cold chain infrastructure. As sponsors continue to diversify their therapeutic pipelines and expand trials globally, clinical trial supply providers play an increasingly vital role in ensuring operational success and compliance. The upward trajectory in trial volume across a wide range of therapeutic areas will continue to reinforce the need for scalable, technology-driven, and patient-centric supply chain solutions in the clinical research ecosystem.

Increased Focus on Personalized Medicine and Biologics

The growing emphasis on personalized medicine and biologics is driving significant expansion in the United States Clinical Trial Supplies Market. Personalized medicine, which tailors treatments based on individual genetic profiles, has increased the demand for precision-based therapies, such as gene therapies, cell therapies, and biologic drugs. These treatments often require complex supply chains to ensure their successful development and clinical testing. Biologic drugs are sensitive to environmental factors such as temperature and handling, necessitating advanced packaging and cold chain logistics to maintain efficacy throughout the trial phases.

As pharmaceutical companies and biotech firms focus on biologics, they face unique challenges in sourcing clinical trial supplies that meet regulatory standards while preserving the integrity of these complex therapies. This has led to a surge in demand for specialized packaging solutions, temperature-controlled transportation, and inventory management tools that are capable of handling sensitive biologic products. The shift toward personalized treatments also requires smaller, more customized clinical trials, often involving fewer patients but with highly specific requirements. This has led to a greater need for precise forecasting, inventory control, and flexible supply chain solutions that can accommodate the scale and complexity of biologic trials.

In addition, the increasing complexity of biologic formulations and the need for more targeted therapeutic approaches require tailored supply chains that can manage specialized components, including active pharmaceutical ingredients (APIs), adjuvants, and biologic formulations. The evolution of biologics and personalized medicine continues to shape the demand for clinical trial supplies that offer enhanced accuracy, security, and compliance with international regulatory frameworks. This shift is expected to accelerate further as advancements in genomics and biotechnology pave the way for more individualized therapies in clinical trials.

Growth in Decentralized and Virtual Clinical Trials

The expansion of decentralized and virtual clinical trials is significantly influencing the growth of the United States Clinical Trial Supplies Market. This shift towards more patient-centric models allows participants to engage in trials from their homes, reducing the need for frequent visits to traditional clinical sites. Advancements in telemedicine, digital health platforms, wearable devices, and remote patient monitoring technologies have facilitated this transformation, enhancing patient participation and retention, especially among populations that were previously underrepresented due to geographical or logistical constraints.​

The U.S. Food and Drug Administration (FDA) has recognized the potential benefits of decentralized clinical trials (DCTs). In its 2023 draft guidance, the FDA highlighted that DCTs could enhance convenience for trial participants, reduce caregiver burden, expand access to diverse populations, and improve trial efficiencies. By enabling remote participation, DCTs can facilitate research on rare diseases and conditions affecting populations with limited mobility. This regulatory support underscores the growing acceptance and implementation of decentralized elements in clinical research.​

As the industry adapts to these changes, the demand for flexible and responsive supply chains has increased. Investigational products, diagnostics, and medical devices now often need to be delivered directly to patients' homes, necessitating direct-to-patient (DTP) logistics services, custom packaging, and real-time tracking solutions. Temperature-sensitive biologics and precision medicines require stringent logistics control, prompting investments in cold chain infrastructure and last-mile connectivity. Ensuring product integrity, patient safety, and regulatory compliance throughout this complex delivery process has created opportunities for specialized logistics companies and technology-enabled supply vendors.​

Pharmaceutical companies and contract research organizations are revisiting their supply strategies to incorporate adaptive planning and demand forecasting models. The variability introduced by remote participation models requires supply chains to be more agile and data-driven, with accurate predictions of enrollment rates, drug usage, and patient adherence. Interactive Response Technologies (IRT) and cloud-based platforms are being leveraged to manage inventory and resupply dynamically, ensuring uninterrupted trial operations.

Download Free Sample Report

Key Market Challenges

Complexity in Managing Global Supply Chains

Managing global supply chains in the clinical trial supplies market presents significant logistical and operational challenges. Clinical trials are increasingly conducted across multiple countries to access diverse patient populations and expedite enrollment. This expansion complicates supply chain coordination due to varying timelines, differing customs regulations, local language requirements, and multiple vendor engagements. Fluctuations in demand forecasts, unpredictable patient enrollment, and protocol amendments further strain supply planning and inventory management. Maintaining drug stability, ensuring timely delivery of investigational products, and preventing stockouts or wastage require highly responsive and adaptive systems. Temperature-sensitive drugs and biologics intensify the need for specialized cold chain logistics and real-time monitoring, which can be expensive and technically demanding. As trials move toward a more decentralized model, with direct-to-patient delivery and remote participation, the supply chain must evolve to provide flexibility without compromising quality or compliance. The cost of addressing these challenges through advanced technologies and robust infrastructure often creates pressure on trial budgets.

Stringent Regulatory Compliance

Regulatory compliance poses another significant hurdle in the clinical trial supplies landscape. Regulatory authorities across regions such as the FDA, EMA, and others enforce stringent guidelines for Good Manufacturing Practices (GMP), labeling, packaging, and distribution of clinical supplies. Each region has its own set of documentation standards, import/export rules, and quality assurance protocols, which can delay trial initiation and complicate global logistics. Frequent updates to regulatory frameworks and variations in interpretation across countries demand constant vigilance and expert oversight. Mislabeling, non-compliant packaging, or temperature excursions can result in penalties, delays, or even trial suspension. Sponsors and supply vendors must invest heavily in training, quality assurance, and compliance systems to align with evolving regulations. Achieving consistency and traceability across a global network while maintaining regulatory integrity is a critical but resource-intensive task in the clinical trial supplies ecosystem.

Key Market Trends

Increased Adoption of Supply Chain Digitalization and Real-Time Monitoring

The increased adoption of supply chain digitalization and real-time monitoring is transforming the operational landscape of the United States Clinical Trial Supplies Market. Pharmaceutical sponsors and contract research organizations are prioritizing end-to-end visibility to manage growing trial complexities, site dispersion, and time-sensitive logistics. Digital platforms such as Interactive Response Technology (IRT), cloud-based inventory systems, and Internet of Things (IoT)-enabled tracking tools are playing a pivotal role in enhancing supply chain responsiveness and transparency. These solutions offer real-time insights into drug availability, temperature control, and shipment progress, allowing supply managers to make proactive decisions that minimize stockouts, wastage, and delays.​

Real-time monitoring tools ensure compliance with strict regulatory requirements by capturing data related to temperature excursions, delivery confirmation, and chain-of-custody records. This capability is especially critical for high-value, sensitive investigational products like biologics and personalized therapies. Predictive analytics integrated with these digital systems can forecast demand fluctuations across trial sites and patient populations, leading to optimized resupply strategies and improved trial continuity. Sponsors benefit from greater control and reduced risk while improving patient experience through more timely and reliable delivery of trial materials.​

Digitalization is also fostering greater collaboration across stakeholders by enabling centralized access to updated supply data, documentation, and reports. It reduces manual errors and paperwork while streamlining processes such as labeling, packaging, and regulatory audits. This shift toward digital-first operations reflects a broader industry commitment to enhancing trial efficiency, compliance, and patient-centricity. As clinical trials become more globalized and complex, real-time digital monitoring is expected to become a standard requirement for ensuring agile and secure supply chain management across all phases of clinical research. The ability to predict and respond swiftly to disruptions positions digitalization as a critical enabler of success in modern clinical trial supply operations.

Rising Outsourcing to Specialized Clinical Supply Providers

The rising trend of outsourcing clinical trial supply services to specialized providers is transforming the operational landscape of the United States Clinical Trial Supplies Market. As clinical trials become more complex, involving multiple sites across various countries and stricter regulatory requirements, pharmaceutical and biotechnology companies are increasingly turning to third-party vendors to handle supply chain logistics. These specialized providers offer expertise in areas such as packaging, labeling, global distribution, comparator sourcing, and return drug accountability, enabling sponsors to focus on core R&D functions while ensuring regulatory compliance and timely trial execution.

Sponsors benefit from the scalability and flexibility these providers offer, especially in adaptive trial designs and multi-phase studies that demand rapid supply chain adjustments. Specialized clinical supply partners often possess established networks and infrastructure, including GMP-compliant facilities, temperature-controlled storage, and real-time inventory tracking systems. Their proficiency in managing customs regulations, local documentation, and international logistics ensures that clinical materials reach trial sites on schedule, minimizing disruptions and patient dropouts. These vendors also help mitigate risks associated with overproduction, stockouts, and drug wastage by leveraging advanced forecasting and supply planning tools.

The shift towards outsourcing is also driven by cost optimization. Building and maintaining in-house supply capabilities for global trials can be resource-intensive, requiring significant investment in personnel, infrastructure, and technology. Outsourcing allows sponsors to convert fixed costs into variable ones, providing financial agility while tapping into the operational excellence of experienced providers. This model supports speed-to-market strategies by enabling faster trial setup and smoother execution, especially in emerging markets or in trials requiring niche or sensitive products like biologics. As drug development timelines shrink and competition intensifies, the strategic role of specialized clinical supply providers continues to grow, making outsourcing a key pillar in the evolution of clinical trial operations across the globe.

Segmental Insights

Clinical Phase Insights

Based on the Clinical Phase, Phase III emerged as the dominant segment in the United States Clinical Trial Supplies Market in 2024. Phase III clinical trials play a critical role in confirming the efficacy, safety, and side-effect profile of a treatment before it receives regulatory approval. These trials typically involve large patient populations across multiple geographic locations and require complex logistics for managing investigational drugs, placebo materials, and comparator drugs. The scale and duration of Phase III trials significantly contribute to higher demand for clinical trial supplies, making this segment dominant in 2024. Pharmaceutical and biotechnology companies invest heavily in this phase due to its decisive role in the commercialization process. As a result, extensive supply chain planning, temperature-controlled storage, labeling, and regulatory compliance are crucial components of Phase III supply management. The increasing number of chronic disease cases and demand for innovative therapies also contributed to the high volume of trials in this phase. In addition, the shift towards personalized medicine and biologics, which require more intricate handling and distribution processes, has reinforced the prominence of Phase III in the market.

Product & Services Insights

Based on the Product & Services, Supply Chain Management emerged as the dominant segment in the United States Clinical Trial Supplies Market in 2024. Supply chain management became the most dominant segment in 2024 due to the increasing complexity and globalization of clinical trials. As studies span multiple countries, managing the logistics of transporting investigational products, ensuring proper storage conditions, and complying with regulatory requirements has become more demanding. Efficient supply chain management ensures timely delivery of materials, reduces delays in study timelines, and helps prevent costly wastage of high-value pharmaceutical products. Companies are investing heavily in digital supply chain solutions, including real-time tracking, temperature monitoring, and demand forecasting tools, to improve operational efficiency and regulatory compliance. The growing trend of decentralized clinical trials, where materials must be shipped directly to patients or local health centers, has intensified the need for sophisticated supply chain solutions.

Download Free Sample Report

Regional Insights

The Mid-West region emerged as the dominant region in the United States Clinical Trial Supplies Market in 2024. This is due to a combination of factors. A key contributor to this growth is the strong presence of major pharmaceutical and biotechnology companies in the region. States like Illinois, Ohio, and Michigan host numerous pharmaceutical and contract research organizations (CROs), making the region a hub for clinical trial activities. The concentration of research institutions and universities also plays a significant role, as these institutions frequently conduct clinical trials, driving the demand for specialized clinical trial supplies. The region benefits from a well-established infrastructure for logistics and distribution, essential for the efficient delivery of clinical trial supplies. Additionally, the Mid-West offers cost-effective operational benefits, with lower labor and operational costs compared to other regions in the U.S. This makes it an attractive location for clinical trial sponsors looking to optimize their supply chain processes. The increasing demand for biologics, advanced therapies, and personalized medicine in the region is fueling the need for specialized supplies, including cold chain storage and transportation solutions.

Recent Developments

• In February 2025, Selkirk Pharma, Inc., a U.S.-based pharmaceutical manufacturer, launched ClinFAST, a new service aimed at accelerating the fill/finish process for injectable clinical trial supplies. Designed specifically for clinical-stage biotech and pharma companies, ClinFAST reduces production timelines while upholding quality standards. The solution addresses industry-wide challenges in securing fill/finish capacity, especially for small-batch projects often overlooked by larger CMOs.
• In January 2025, MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, announced a clinical supply agreement with BeiGene, a global oncology company. The collaboration aims to evaluate the efficacy of MAIA's telomere-targeting anticancer agent, THIO, in combination with BeiGene’s immune checkpoint inhibitor, tislelizumab, across three cancer indications. The Phase 2 trials, which are single-arm pivotal studies, will investigate the drug combination's effectiveness in hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), and colorectal cancer (CRC).
• In July 2024, Catalent, Inc. announced the completion of its clinical supply facility expansion in Schorndorf. The Schorndorf site, Catalent’s main European facility, provides key services including packaging, storage, and distribution for clinical trials. The expansion adds 32,000 square feet (3,000 square meters) to the facility, enhancing storage and handling capabilities for clinical trial materials at controlled room temperatures (15-25°C). The new space also includes a fully automated bottle filling line and a dedicated area for Catalent’s FastChain demand-led supply service.
• In December 2023, NiKang Therapeutics Inc., a clinical-stage biotech company focused on oncology, announced a clinical trial collaboration and supply agreement with Roche. The partnership will evaluate NKT2152, a small molecule targeting hypoxia-inducible factor 2α (HIF2α), in combination with Roche's atezolizumab (Tecentriq) and bevacizumab (Avastin) for first-line treatment of advanced or unresectable hepatocellular carcinoma (HCC). The collaboration will leverage Roche’s MORPHEUS-LIVER phase 1b/2 platform for efficient combination development.

Key Market Players

• Thermo Fisher Scientific Inc.
• Marken (UPS)
• PCI Pharma Services
• Sharp Services LLC
• Cencora, Inc.
• Myonex
• Parexel International Corporation
• IQVIA
• Novo Holdings A/S
• ICON Plc

Report Scope:

In this report, the United States Clinical Trial Supplies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• United States Clinical Trial Supplies Market, By Clinical Phase:

o   Phase I

o   Phase II

o   Phase III

o   Others

• United States Clinical Trial Supplies Market, By Product & Services:

o   Manufacturing

o   Storage & Distribution

o   Supply Chain Management

• United States Clinical Trial Supplies Market, By Therapeutic Use:

o   Oncology

o   CNS Diseases

o   Cardiovascular Diseases

o   Infectious Disease

o   Metabolic Disorders

o   Others

• United States Clinical Trial Supplies Market, By End User:

o   Pharmaceutical

o   Biologics

o   Medical device

o   Others

• United States Clinical Trial Supplies Market, By Region:

o   North-East

o   Mid-West

o   West

o   South

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the United States Clinical Trial Supplies Market.

Available Customizations:

United States Clinical Trial Supplies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

United States Clinical Trial Supplies Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com